English

IMPEL PHARMACEUTICALS INC.

EDGAR

IMPL Filing (EFFECT) · filed 2024-02-16

17 filing records in this dataset, filed from 2021-04-02 to 2024-02-16. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

5.02 million USD

2023 Q3 · USD

Exact inputs and evidence

Revenue: 5023000 USD Source

Operating margin

-255.05%

2023 Q3 · %

Exact inputs and evidence

Operating Income: -12811000 USD Source
Revenue: 5023000 USD Source

Operating cash flow

-16.5 million USD

2023 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -61107000 USD Source
Operating Cash Flow: -44583000 USD Source

Free cash flow

-17.5 million USD

2023 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -61107000 USD Source
Operating Cash Flow: -44583000 USD Source
Capital Expenditure: 1871000 USD Source
Capital Expenditure: 914000 USD Source

Cash and cash equivalents: 200 thousand USD 2023-09-30 Source
Exact value

200000 USD
Long-term debt including current maturities: 29.5 million USD 2021-12-31 Source
Exact value

29450000 USD
Shares outstanding: 23.7 million shares 2023-09-30 Source
Exact value

23749005 shares

Reported share-count change

0.04% · 9.69 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

23739313 shares · 2022-09-30· Source
23749005 shares · 2023-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

21 million USD

2022-10-01 – 2023-09-30

Exact inputs and evidence

Revenue: 12652000 USD · 2022-01-01 – 2022-12-31 Source
Revenue: 7644000 USD · 2022-01-01 – 2022-09-30 Source
Revenue: 4372000 USD · 2023-01-01 – 2023-03-31 Source
Revenue: 6584000 USD · 2023-04-01 – 2023-06-30 Source
Revenue: 5023000 USD · 2023-07-01 – 2023-09-30 Source

Net income

-74.3 million USD

2022-10-01 – 2023-09-30

Exact inputs and evidence

Net income: -106312000 USD · 2022-01-01 – 2022-12-31 Source
Net income: -83271000 USD · 2022-01-01 – 2022-09-30 Source
Net income: -30067000 USD · 2023-01-01 – 2023-03-31 Source
Net income: -7357000 USD · 2023-04-01 – 2023-06-30 Source
Net income: -13814000 USD · 2023-07-01 – 2023-09-30 Source

Operating cash flow

-79.1 million USD

2022-10-01 – 2023-09-30

Exact inputs and evidence

Operating cash flow: -93642000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -75656000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -24143000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -44583000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -24143000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -61107000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -44583000 USD · 2023-01-01 – 2023-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-02-16.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2022-12-31
Operating income: 4 of 11 periods available· newest 2022-12-31
Net income: 4 of 11 periods available· newest 2022-12-31
Operating cash flow: 4 of 11 periods available· newest 2022-12-31
Capital expenditure: 4 of 11 periods available· newest 2022-12-31
Total assets: 2 of 11 periods available· newest 2022-12-31
Total liabilities: 2 of 11 periods available· newest 2022-12-31
Current assets: 2 of 11 periods available· newest 2022-12-31
Current liabilities: 2 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 2 of 11 periods available· newest 2022-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2021-12-31
Shares outstanding: 2 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+1,794%

Prior period

USD 668,000

2021-01-01 – 2021-12-31
Current period

USD 12.65 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

12652000 − 668000 = 11984000 USD

668000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
12652000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · IMPEL PHARMACEUTICALS INC. · 2022-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Year-over-year change in Revenue: 11984000 USD Concept: fundies:Revenue Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 12652000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#1648556 Filing: 000095017023009981 Input fundies:Revenue: 668000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#1650534 Filing: 000095017023009981
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 29.78 million

Prior period

−USD 76.54 million

2021-01-01 – 2021-12-31
Current period

−USD 106.31 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-106312000 − -76536000 = -29776000 USD

-76536000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-106312000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · IMPEL PHARMACEUTICALS INC. · 2022-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Year-over-year change in Net income: -29776000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -106312000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#1981709 Filing: 000095017023009981 Input fundies:NetIncome: -76536000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#1913236 Filing: 000095017023009981
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 27.28 million

Prior period

−USD 66.36 million

2021-01-01 – 2021-12-31
Current period

−USD 93.64 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-93642000 − -66364000 = -27278000 USD

-66364000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-93642000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · IMPEL PHARMACEUTICALS INC. · 2022-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Year-over-year change in Operating cash flow: -27278000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -93642000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#2094967 Filing: 000095017023009981 Input fundies:OperatingCashFlow: -66364000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#2097334 Filing: 000095017023009981
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+237.5%

Prior period

USD 408,000

2021-01-01 – 2021-12-31
Current period

USD 1.38 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

1377000 − 408000 = 969000 USD

408000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
1377000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · IMPEL PHARMACEUTICALS INC. · 2022-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Year-over-year change in Capital expenditure: 969000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1377000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#2103104 Filing: 000095017023009981 Input fundies:CapitalExpenditure: 408000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#2105396 Filing: 000095017023009981
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 12.65 million 100% of revenue
Cost of revenue USD 6.5 million 51% of revenue
Operating expenses USD 89.34 million 706% of revenue
Operating income −USD 83.18 million −657% of revenue
Tax, interest and other Derived USD 23.13 million 183% of revenue
Net income −USD 106.31 million −840% of revenue

Cash

Operating cash flow −USD 93.64 million −740% of revenue
Capital expenditure USD 1.38 million 11% of revenue
Free cash flow Derived −USD 95.02 million −751% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2021 Operating loss: operating costs were 10,801% of revenue.
2022 Operating loss: operating costs were 757% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2021 2021-01-01 – 2021-12-31	668000	72154000 Derived	-71486000	5050000 Derived	-76536000	-66772000 Derived	Source 2021-01-01 – 2021-12-31: 668000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -71486000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -76536000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -66364000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 408000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	12652000	95836000 Derived	-83184000	23128000 Derived	-106312000	-95019000 Derived	Source 2022-01-01 – 2022-12-31: 12652000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -83184000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -106312000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -93642000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 1377000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 12.7M 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Revenue	668000	Revenue: 668000 Open source
20222022-12-31	Revenue	12652000	Revenue: 12652000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

1,794% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Year over year	No prior comparable period	Revenue: 668000 Open source
20222022-12-31	Year over year	1,794%	Revenue: 12652000 Open source Revenue: 668000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -657.5% 2022

Net margin -840.3% 2022

Free cash flow margin -751% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Operating margin	-10,701.5%	Operating Income: -71486000 Open source Revenue: 668000 Open source
20222022-12-31	Operating margin	-657.5%	Operating Income: -83184000 Open source Revenue: 12652000 Open source
20212021-12-31	Net margin	-11,457.5%	Net Income: -76536000 Open source Revenue: 668000 Open source
20222022-12-31	Net margin	-840.3%	Net Income: -106312000 Open source Revenue: 12652000 Open source
20212021-12-31	Free cash flow margin	-9,995.8%	Revenue: 668000 Open source Operating Cash Flow: -66364000 Open source Capital Expenditure: 408000 Open source
20222022-12-31	Free cash flow margin	-751%	Revenue: 12652000 Open source Operating Cash Flow: -93642000 Open source Capital Expenditure: 1377000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -93.6M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Operating cash flow	-66364000	Operating Cash Flow: -66364000 Open source
20222022-12-31	Operating cash flow	-93642000	Operating Cash Flow: -93642000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -95M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Free cash flow	-66772000	Operating Cash Flow: -66364000 Open source Capital Expenditure: 408000 Open source
20222022-12-31	Free cash flow	-95019000	Operating Cash Flow: -93642000 Open source Capital Expenditure: 1377000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

149.9% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Liabilities / assets	46.4%	Total Liabilities: 45404000 Open source Total Assets: 97912000 Open source
20222022-12-31	Liabilities / assets	149.9%	Total Liabilities: 132707000 Open source Total Assets: 88550000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.6× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Current assets / current liabilities	5.93×	Current Assets: 94576000 Open source Current Liabilities: 15954000 Open source
20222022-12-31	Current assets / current liabilities	3.6×	Current Assets: 79809000 Open source Current Liabilities: 22163000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 41.86 million Exact value Exact value: -41859000 USD 2019-01-01 – 2019-12-31: -41859000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMPEL PHARMACEUTICALS INC. · 2019-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Net Income: -41859000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -41859000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000119312521266581/d593533ds1.htm#2275017 Filing: 000119312521266581 The citation records this snapshot. The page link may show a newer release later.	−USD 36.49 million Exact value Exact value: -36487000 USD 2019-01-01 – 2019-12-31: -36487000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMPEL PHARMACEUTICALS INC. · 2019-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Operating Cash Flow: -36487000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -36487000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000119312521266581/d593533ds1.htm#2341260 Filing: 000119312521266581 The citation records this snapshot. The page link may show a newer release later.	USD 1.52 million Exact value Exact value: 1523000 USD 2019-01-01 – 2019-12-31: 1523000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMPEL PHARMACEUTICALS INC. · 2019-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Capital Expenditure: 1523000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1523000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000119312521266581/d593533ds1.htm#2344686 Filing: 000119312521266581 The citation records this snapshot. The page link may show a newer release later.	−USD 38.01 million Calculation and evidence -36487000 − 1523000 USD Exact free cash flow: -38010000 USD 2019-01-01 – 2019-12-31: -36487000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1523000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMPEL PHARMACEUTICALS INC. · 2019-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Free cash flow: -38010000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -36487000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000119312521266581/d593533ds1.htm#2341260 Filing: 000119312521266581 Input fundies:CapitalExpenditure: 1523000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000119312521266581/d593533ds1.htm#2344686 Filing: 000119312521266581 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 45.8 million Exact value Exact value: -45798000 USD 2020-01-01 – 2020-12-31: -45798000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMPEL PHARMACEUTICALS INC. · 2020-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Net Income: -45798000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -45798000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017022004939/impl-20211231.htm#2002394 Filing: 000095017022004939 The citation records this snapshot. The page link may show a newer release later.	−USD 39.18 million Exact value Exact value: -39183000 USD 2020-01-01 – 2020-12-31: -39183000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMPEL PHARMACEUTICALS INC. · 2020-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Operating Cash Flow: -39183000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -39183000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017022004939/impl-20211231.htm#2243125 Filing: 000095017022004939 The citation records this snapshot. The page link may show a newer release later.	USD 1.78 million Exact value Exact value: 1782000 USD 2020-01-01 – 2020-12-31: 1782000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMPEL PHARMACEUTICALS INC. · 2020-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Capital Expenditure: 1782000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1782000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017022004939/impl-20211231.htm#2250307 Filing: 000095017022004939 The citation records this snapshot. The page link may show a newer release later.	−USD 40.97 million Calculation and evidence -39183000 − 1782000 USD Exact free cash flow: -40965000 USD 2020-01-01 – 2020-12-31: -39183000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1782000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMPEL PHARMACEUTICALS INC. · 2020-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Free cash flow: -40965000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -39183000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017022004939/impl-20211231.htm#2243125 Filing: 000095017022004939 Input fundies:CapitalExpenditure: 1782000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017022004939/impl-20211231.htm#2250307 Filing: 000095017022004939 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 76.54 million Exact value Exact value: -76536000 USD 2021-01-01 – 2021-12-31: -76536000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMPEL PHARMACEUTICALS INC. · 2021-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Net Income: -76536000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -76536000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#1913236 Filing: 000095017023009981 The citation records this snapshot. The page link may show a newer release later.	−USD 66.36 million Exact value Exact value: -66364000 USD 2021-01-01 – 2021-12-31: -66364000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMPEL PHARMACEUTICALS INC. · 2021-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Operating Cash Flow: -66364000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -66364000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#2097334 Filing: 000095017023009981 The citation records this snapshot. The page link may show a newer release later.	USD 408,000 Exact value Exact value: 408000 USD 2021-01-01 – 2021-12-31: 408000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMPEL PHARMACEUTICALS INC. · 2021-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Capital Expenditure: 408000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 408000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#2105396 Filing: 000095017023009981 The citation records this snapshot. The page link may show a newer release later.	−USD 66.77 million Calculation and evidence -66364000 − 408000 USD Exact free cash flow: -66772000 USD 2021-01-01 – 2021-12-31: -66364000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 408000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMPEL PHARMACEUTICALS INC. · 2021-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Free cash flow: -66772000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -66364000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#2097334 Filing: 000095017023009981 Input fundies:CapitalExpenditure: 408000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#2105396 Filing: 000095017023009981 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 106.31 million Exact value Exact value: -106312000 USD 2022-01-01 – 2022-12-31: -106312000 USD Inspect Net Income Open source Share or cite Citation for Net Income · IMPEL PHARMACEUTICALS INC. · 2022-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Net Income: -106312000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -106312000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#1981709 Filing: 000095017023009981 The citation records this snapshot. The page link may show a newer release later.	−USD 93.64 million Exact value Exact value: -93642000 USD 2022-01-01 – 2022-12-31: -93642000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · IMPEL PHARMACEUTICALS INC. · 2022-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Operating Cash Flow: -93642000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -93642000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#2094967 Filing: 000095017023009981 The citation records this snapshot. The page link may show a newer release later.	USD 1.38 million Exact value Exact value: 1377000 USD 2022-01-01 – 2022-12-31: 1377000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · IMPEL PHARMACEUTICALS INC. · 2022-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Capital Expenditure: 1377000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1377000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#2103104 Filing: 000095017023009981 The citation records this snapshot. The page link may show a newer release later.	−USD 95.02 million Calculation and evidence -93642000 − 1377000 USD Exact free cash flow: -95019000 USD 2022-01-01 – 2022-12-31: -93642000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 1377000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · IMPEL PHARMACEUTICALS INC. · 2022-12-31 IMPEL PHARMACEUTICALS INC. (edgar:1445499) Free cash flow: -95019000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T14:51:11Z Snapshot: f039b969b4153946fe045728072ff7773d183307353e5472d9cfd90dd5549025 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1445499?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -93642000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#2094967 Filing: 000095017023009981 Input fundies:CapitalExpenditure: 1377000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1445499/000095017023009981/impl-20221231.htm#2103104 Filing: 000095017023009981 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

17 filings · 1,069 latest values · 1,069 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001445499, 1445499, IMPL, IMPLQ, edgar:1445499

Also known as IMPEL NEUROPHARMA INC, IMPEL NEUROPHARMA, INC., IMPEL PHARMACEUTICALS INC, IMPEL PHARMACEUTICALS INC., IPI Legacy Liquidation Co

IMPEL PHARMACEUTICALS INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation